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Abstract 
Human saliva plays a pivotal role in digesting food and maintaining oral hygiene. The presence of 
electrolytes, mucus, glycoproteins, enzymes, antibacterial compounds, and gingival crevicular fluid in 
saliva ensures the optimum condition of oral cavity and general health condition. Saliva collection has 
been proven non-invasive, convenient, and inexpensive compared to conventional venipuncture pro-
cedure. These distinctive advantages provide a promising potential of saliva as a diagnostic fluid. 
Through comprehensive analysis, an array of salivary proteins and peptides may be beneficial as bi-
omarkers in oral and systemic diseases. In this review, we discuss the utility of human salivary pro-
teomes and tabulate the recent salivary biomarkers found in subjects with acute myocardial infarction as 
well as respective methods employed. In a clinical setting, since acute myocardial infarction contributes 
to large cases of mortality worldwide, an early intervention using these biomarkers will provide an 
effective solution to reduce global heart attack incidence particularly among its high-risk group of type-2 
diabetes mellitus patients. The utility of salivary biomarkers will make the prediction of this cardiac 
event possible due to its reliability hence improve the quality of life of the patients. Current challenges 
in saliva collection are also addressed to improve the quality of saliva samples and produce robust 
biomarkers for future use in clinical applications. 
Key words: saliva; biomarker; acute myocardial infarction; proteomics; type-2 diabetes mellitus 
Introduction 
Human saliva is a biological fluid with myriad of 
biological functions important for the maintenance of 
oral and general health. It is a plasma ultra-filtrate 
containing proteins either synthesized in situ from 
blood or in the salivary glands [1]. Major salivary 
glands consisting of submandibular glands, sublin-
gual glands, and parotid glands lie at the vicinity of 
the oral cavity whereas other minor exocrine glands 
lie beneath the oral mucosa [2]. Several roles of saliva 
in the oral cavity include lubrication and binding, 
solubilisation of dry food, oral hygiene, and initiation 
of starch digestion [3]. Apart from water as its major 
constituent, whole saliva also contains bacterial and 
exfoliated cells, electrolytes, glycoproteins, enzymes, 
and antibacterial compounds. Likewise, minute 
amounts of gingival crevicular fluid coexist with sa-
liva in the gingival crevice surrounding the teeth [4].  
Changes in saliva quality and quantity are in-
dicative of the wellness of the patient [5]. Human sa-
liva, as a mirror of oral and systemic health, provides 
valuable information because it contains biomarkers 
specific for the unique physiologic aspects of perio-
dontal and systemic diseases. Proteomic markers 
from immunoglobulins to bone remodelling proteins 
were previously discovered in existing periodontal 
diseases [6]. In one study, salivary epidermal growth 
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factor was found to be significantly raised in women 
with active and nonactive breast cancer compared to 
healthy women [7]. Compared to blood, saliva has 
been clinically shown to produce more accurate, in-
expensive, and convenient results. The diagnostic 
potential of this fluid has been studied in many la-
boratories in order to find its advantages over other 
biological fluids and potential biomarkers in numer-
ous diseases. Unlike plasma, saliva can be readily 
used for tests since it will not clot. Its noninvasive 
approach renders this biological fluid an effective 
alternative to blood and urine testing in monitoring 
patient’s health condition [8]. 
Whole saliva can be easily collected by drooling, 
spitting, or swabbing into a designated tube as op-
posed to invasive blood collection procedure. These 
methods of obtaining saliva pose minimal risk of 
contracting deadly pathogens to the healthcare pro-
fessionals. Plus, sufficient quantities of saliva can be 
easily obtained for analysis by a practitioner even 
with modest training. For diagnostic and research 
purposes, saliva collection kits have been commer-
cially marketed worldwide including Or-
agene.DISCOVER from DNA Genotek Inc., Ul-
traSal-2™ from Oasis Diagnostics, OraSure® Oral 
Specimen Collection Device from OraSure Technolo-
gies, Inc., Certus® Collection Device from Alere™, and 
Saliva Collection System from Greiner Bio-One. In one 
study, budget estimates for both blood and saliva 
collections were developed by a group of scientists 
incorporating personnel expenses and corresponding 
collection methods into the calculation. When com-
paring both budget estimates, saliva collection was 
proven to be 48% less costly than blood collection [9]. 
These advantages have attracted many researchers to 
study and identify potential salivary biomarkers with 
unparalleled opportunities for clinical applications. 
As illustrated in Figure 1, human salivary pro-
teomes exhibit promising potential as biomarkers to 
predict the onset of acute myocardial infarction 
(AMI), or heart attack. On a global scale, the disease 
remains the primary cause of morbidity and mortali-
ty. This pathologic event occurs as a result of acute 
myocardial ischemia when there is evidence of myo-
cardial necrosis [10]. According to World Health Or-
ganization [11], this disease is one of the major forms 
of cardiovascular disease (CVD) in which its preva-
lence constitutes approximately 48% of all deaths in 
2008, affecting more than 17 million patients around 
the globe. Other AMI complications may include se-
vere cardiac disability upon survival of the onset [12].  
Since AMI is the leading cause of death world-
wide, this disease has been selected among other sys-
temic diseases in this review. Recent salivary findings 
and progress pertaining to this condition will be dis-
cussed to elucidate the promising use of saliva as a 
diagnostic fluid in acute cardiac care among a very 
high-risk group of type-2 diabetes mellitus (T2DM), as 
well as relevant methods employed. Current chal-
lenges in saliva collection will be highlighted for fur-
ther improvement on the quality of salivary bi-
omarkers discovered in future. 
Human salivary proteomes as biomarkers 
Biomarkers can be indicative of a specific physi-
ological or pathological state of a biological fluid in-
cluding blood and saliva [13]. Many researchers 
worldwide have been studying the use of biomarkers 
due to its ability to monitor susceptibility, progres-
sion, and resolution of diseases, health condition, and 
treatment outcome. Despite the variability of the term 
“biomarker” used in diverse aspects of its applica-
tions, the most comprehensible definition of bi-
omarker is “cellular, biochemical, molecular, or ge-
netic alterations by which a normal, abnormal, or 
simple biological process can be recognized or moni-
tored” [14]. Any molecular species which demon-
strates significant variation in concentration, as com-
pared to those of control subjects, is a potential bi-
omarker. Therefore, if expression of interleukin-1 re-
ceptor antagonist is significantly enhanced compared 
to the normal group, the protein can be potentially 
targeted as an early biomarker to indicate risks of 
tobacco-related diseases [15].  
 
Figure 1. Summary of the advantages and disadvantages of saliva as a diagnostic fluid in relation to AMI. 
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Saliva contains biomarkers derived from serum, 
gingival crevicular fluid, and mucosal transudate 
which are useful in multiplexed assays that are being 
developed as point-of-care devices, rapid tests, or in 
more standardized formats for centralized clinical 
laboratory operations [16]. The prospect of salivary 
diagnosis appeals to many scientists around the world 
for disease prognosis and diagnosis. Current discov-
eries on potential salivary biomarkers encompass 
various systemic diseases such as autoimmune dis-
eases, bone turnover markers, cardiovascular mark-
ers, dental caries and periodontal diseases, diseases of 
the adrenal cortex, drug level monitoring, forensic 
evidence, genetic disorders, infections, malignancy, 
occupational and environmental medicine, psycho-
logical research, and renal diseases [17]. In oral 
squamous cell carcinoma, Ni et al. [18] acquired sev-
eral potential salivary biomarkers corresponding to 
early detection and evaluation of aggressiveness and 
occurrence of the cancer based on recent researches. 
As such, further salivary investigation can yield more 
comprehensive information about this fluid especially 
in the field of health medicine. 
Apart from genomics and metabolomics, sali-
vary proteomics [19] has demonstrated a great poten-
tial and has been widely utilised as a means to iden-
tify candidate biomarkers and possible immuno-
chemistry markers for various illnesses predomi-
nantly infectious and neoplastic diseases [20]. In pep-
tide identification, Mass Spectrometry (MS)-based 
proteomic techniques have been commonly applied 
including two-dimensional gel electrophoresis-mass 
spectrometry (2-DE/MS), liquid chromatography 
tandem mass spectrometry (LC-MS/MS), ma-
trix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-ToF/MS), and sur-
face-enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-ToF/MS) 
[21]. By employing one of MS-based proteomic tech-
niques, Chan et al. [22] detected significant altered 
abundance of polymeric immunoglobulin receptor, 
plastin-2, actin related protein 3, leukocyte elastase 
inhibitor, carbonic anhydrases 6, immunoglobulin J, 
and interleukin-1 receptor antagonist among T2DM 
patients with periodontitis compared to their control 
T2DM cohorts. Additionally, Jessie et al. [23, 24] de-
tected increased abundance and structural microhet-
erogeneity of haptoglobin beta chains in the saliva of 
patients with oral squamous cell carcinoma which 
were also subsequently observed in the saliva of ha-
bitual betel quid chewers. Many other salivary bi-
omarkers with diagnostic potential were already 
characterised in oncology, head and neck carcinoma, 
breast and gastric cancers, salivary gland function and 
disease, Sjögren syndrome, systemic sclerosis, dental 
and gingival pathology, systemic, psychiatric, and 
neurological diseases using MS-based proteomics 
[25]. It is possible that efficiency and accuracy of these 
proteomic technologies will turn salivary diagnostics 
into a clinical reality. 
Salivary proteomes in relation to AMI 
The prospect of utilizing saliva samples in the 
diagnosis of AMI is appealing to a large group of 
scientists due to its noninvasive and economical na-
ture. Extensive biomarker research on CVD has elu-
cidated various proteins associated with this disease. 
Since approximately 27% of the whole saliva proteins 
resemble those found in plasma [26], similar proteins 
present in both saliva and plasma will be very useful 
to facilitate monitoring of both disease progression 
and therapeutic treatments among these patients. In 
association with AMI, some studies on plasma pro-
teins revealed significant biomarkers involved in 
myocardial injury, myocardial stress, inflammation, 
neuroendocrine activation, atherosclerotic process, 
platelet activation, plaque instability, endothelial 
dysfunction, oxidative stress, and myocardial stretch. 
Out of all these proteins, natriuretic peptides, 
C-reactive protein (CRP), creatine kinase (CK), and 
cardiac troponin were included as commonly used 
cardiac biomarkers in acute cardiac care [27]. In a 
clinical setting, a kit for measuring human salivary 
CRP, a common biomarker related to cardiovascular 
inflammation, has been developed by Salimetrics®. 
Another recent cutting-edge technology is Oral Fluid 
NanoSensor Test (OFNASET) which provides porta-
ble, cheap, accurate, definitive, and quantitative re-
sults. Besides its intended use in oral cancer, this par-
ticular alternative can possibly benefit the 
point-of-care multiplex detection of salivary bi-
omarkers among AMI patients [28]. Given the 
above-mentioned clinical benefits of saliva collection, 
a patient’s salivary proteome should be very useful in 
determining heart condition of the patient in order to 
predict AMI. Several studies have demonstrated sal-
ivary biomarkers associated with AMI, as shown in 
Table 1. By comparing these salivary biomarkers with 
those in plasma, as elaborated by Kossaify et al. [27], 
CRP, CK, CD40 ligand, cardiac troponin I, cardiac 
troponin T, some families of interleukin (IL), tumour 
necrosis factor alpha, matrix metalloproteinase 
(MMP), and myeloperoxidase share similarities with 
plasma biomarkers which also play significant roles in 
inflammation and plaque instability (Figure 2). Alt-
hough these discoveries may enlighten the diagnostic 
utility of salivary proteomes as biomarkers in relation 
to CVD, none of the salivary biomarkers listed above 
have been verified to predict the onset of AMI. All of 
these studies, as tabulated in table 1, were conducted 
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retrospectively after the incidence. On the other hand, 
prospective studies should be able to alternatively 
facilitate the researchers to find predictive AMI bi-
omarkers. In future, these newly detected salivary 
biomarkers will conceivably provide an early molec-
ular diagnosis and eventually increase the survival 
rate of cardiovascular patients as opposed to that of 
plasma. However, more validation needs to be carried 
out in order to find robust and discriminatory bi-
omarkers for this disease. 
Susceptibility of AMI among patients with 
type-2 diabetes mellitus  
T2DM is an inflammatory illness with a clear-cut 
relationship with CVD. This is validated when heart 
disease and stroke constitute no less than 70 percent 
of mortality among people with this metabolic disor-
der [39], rendering the T2DM patients to fall into a 
high-risk group to be later inflicted by AMI. In fact, 
prevalence of T2DM cases is becoming a worldwide 
threat. The incidence of this disease has alarmingly 
doubled over the last three decades [40]. T2DM is 
initially preceded by insulin resistance and hyperin-
sulinemia, both of which are related with cardiovas-
cular risk factors such as obesity, hypertension, lipid 
abnormalities, and endothelial dysfunction [41]. 
Consequently, when the heart loses the ability to 
pump blood effectively, congestive heart failure oc-
curs which is often contributory to the later onset of 
AMI. Haffner et al. [42] discovered that the risk of 
adults with T2DM to suffer from CVD is two to four 
times higher than that of adults without the disorder. 
 
 
Figure 2. Comparison of plasma and salivary biomarkers in relation to 
AMI. NP: natriuretic peptide; h-FABP: heart-type fatty-acid binding protein; 
MR-proADM: midregional-proadrenomedullin; CgA: chromogranin A; 
sLOX-1: soluble lectin-like oxidized low-density lipoprotein receptor-1; 
Lp-PLA2: lipoprotein-associated phospholipase A2; GGT: gamma-glutamyl 
transferase; ANP: atrial natriuretic peptide; TNF-α: tumour necrosis 
factor- alpha; cTn: cardiac troponin; MMP: matrix metalloproteinase; MPO: 
myeloperoxidase; SAA: salivary alpha-amylase; GRO-α: growth related 
oncogene-alpha; sICAM-1: soluble intercellular adhesion molecule-1 
 
 
Table 1. Salivary biomarkers associated with AMI. 
Significant Associated Proteins Subjects Methods Saliva Reference 
CRP, CK-MB, sCD40 ligand 92 + 105 control Beadlyte technology (Luminex®) and enzyme 
immunoassays 
UWS [29] 
Decreased irisin, increased troponin-I, CK, CK-MB 11 + 14 control Enzyme immunoassay Submandibular/ 
Sublingual/Parotid 
[30] 
Increased ischemia-modified albumin 60 + 40 control Colorimetric assay UWS [31] 
Increased cTnI* 30 + 28 control Enzyme immunoassay UWS/SWS [32] 
Increased hs-cTnT 30 + 30 control Enzyme immunoassay UWS/SWS [33] 
Increased SAA 85 + 388 control Kinetic enzyme assay UWS [34] 
Increased CK-MB 30 + 30 control Immunoinhibition assay UWS [35] 
Increased CK 30+ 30 control IFCC UWS [36] 
Increased polymorphonuclear leukocyte MMP-8 47 + 28 control Immunofluorometric assay and immunoblot 
densitometric analysis 
SWS [37] 
Increased CRP, MMP-9, IL-1β, sICAM-1, MPO, adiponec-
tin, monocyte chemoattractant protein 1, GRO-α, de-
creased TNF-α, sCD40 ligand, IL-6 
41 + 43 control Beadlyte technology (Luminex®) and enzyme 
immunoassays 
UWS [38] 
SWS: stimulated whole saliva; UWS: unstimulated whole saliva; sCD40: ligand soluble CD40 ligand; cTnI: cardiac troponin I; hs-cTnT: hyper-sensitivity cardiac troponin T: 
SAA: salivary alpha-amylase; IFCC: International Federation of Clinical Chemistry; MPO: myeloperoxidase; sICAM-1: soluble intercellular adhesion molecule-1; GRO-α: 
growth-related oncogene-alpha; TNF-α: tumour necrosis factor-alpha. *Only found in UWS 
 
 
Between 2010 and 2030, the number of T2DM 
cases is projected to increase by 69% in developing 
countries and by 20% in developed countries [43]. An 
upsurge projection of the number of T2DM adults in 
developing countries is strongly associated with 
adoption of Western lifestyle due to overconsumption 
of inexpensive, high-calorie food, and sedentary rou-
tine. The resulting potent obesity rapidly escalates the 
percentages of diabetic incidence in these developing 
nations which are already stricken under the burden 
of communicable diseases such as lower respiratory 
tract infections, acquired immune deficiency syn-
drome (AIDS), diarrheal diseases, and others [44]. To 
date, practitioners in the U.S. have recommended 
diverse cardiac tests to diagnose coronary heart 
disease despite the limitation that no individual test is 
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sufficiently reliable [45]. The tests may incorporate 
electrocardiogram, stress testing, echocardiography, 
chest x-ray, blood tests, electron-beam computed 
tomography, coronary angiography, and cardiac 
catherization. Thus far, none of these tests are 
adequately relevant to the prediction of infarction in 
the majority of individuals tested, even if their 
biochemical results are also supplemented to foresee 
the cardiac event. Likewise, in developing countries, 
the lofty costs of highly-trained practicioners, 
hospitalizations, and these tests are inherently 
unfeasible [46]. For this reason, prospective patients 
from these regions are more likely to forgo the testing 
process and leave themselves undetected until 
reaching the chronic stage. Due to the reliability and 
inexpensive nature of saliva collection, salivary di-
agnosis can be easily aimed at these high-risk patients 
residing in developing regions. Consequently, this 
method is expected to revamp the current health sys-
tem and increase the availability of accurate diagnos-
tics in remote and impoverished areas. 
In a proteomic research of salivary biomarkers, 
Rao et al. [47] identified 487 unique proteins correlated 
with T2DM of which 33% of these had not been pre-
viously reported in human saliva. Sixty-five proteins 
were markedly expressed between control and T2DM 
samples predominantly involved in regulating me-
tabolism and immune response pathways. Even 
though extensive studies have been conducted by 
scientists around the globe pertaining to respective 
diseases of T2DM and AMI, it is still paramount for 
the practitioners to be able to predict the onset of AMI 
among T2DM patients due to its strong propensity. A 
review conducted by Syed Ikmal et al. suggested 
YKL-40, alpha-hydroxybutyrate, soluble CD36, leptin, 
resistin, interleukin-18, retinol binding protein-4, and 
chemerin, some of which may be present in saliva, 
could act as predictors of cardiovascular events in 
diabetic patients. [48]. Practically, a T2DM patient 
diagnosed with an enhanced level of any clotting 
proteins or inflammatory markers in saliva should be 
regularly monitored for an early intervention prior to 
the onset of AMI. In future, the generated database of 
these biomarkers will provide an instructive reference 
to assess the susceptibility of T2DM patients to heart 
condition, hence reducing morbidity and mortality 
associated with AMI and improving the quality of life 
of the patients predominantly from developing na-
tions. 
Current challenges 
Saliva diagnostic tests can be potentially used 
within a wide range of clinical applications including 
population-based screening programs, confirmatory 
diagnosis, risk stratification, prognosis determination, 
and therapy response monitoring. Nevertheless, de-
creasing the number of false-negative and 
false-positive test result outcomes should be invaria-
bly taken into consideration in order to maintain the 
quality of patient diagnosis and therapy [49]. 
In certain cases, some salivary proteomes may be 
spuriously discovered as biomarkers within a large 
pool of samples. One reason is certain peptides may 
have been subjected to modifications resulting to 
polymorphic isoforms and post translational modifi-
cations [50]. Numerous salivary proteins were re-
vealed to exist in polymorphic forms. For instance, 
genetic polymorphisms in CA6 gene influence the 
expression and catalytic activity of human salivary 
carbonic anhydrase VI [51]. Protein degradation in 
whole saliva also plays a role in the variety of pep-
tides observed. Takehara and her co-workers [52] 
proposed that the N-terminal region of mucin 7 was 
particularly prone to proteolytic degradation due to 
varying biological states of the human body. Another 
study conducted by Sun et al. [53] proved that many 
salivary glycoproteins were associated with age, 
gender, and immunity. It is also noteworthy that even 
though passive drooling, paraffin gum, and Salivette® 
collection methods cover whole saliva proteome, spe-
cific proteins observed are dependent on the collec-
tion approach [54].  
In addition, older age is often associated with a 
number of cases related to functional limitations, 
heart failure, prior coronary disease, and renal insuf-
ficiency [55]. As a result, saliva collection can pose a 
challenge among older T2DM patients. For example, 
geriatric patients are prone to xerostomia upon med-
ications with anticholinergic properties, dehydration, 
diabetes, and radiotherapy for head and neck cancer 
[56]. Dry mouth will limit the amount of sample col-
lected and compromise its subsequent results. Insuf-
ficient sample volume obtained will possibly resort to 
loss of patients during the study. Some alternative 
sample collection approaches have been evaluated 
such as passive drool, filter paper, and microsponges 
but each individual approach has its own advantages 
and disadvantages in terms of sufficient sample re-
covery [57]. Since there is no concrete resolution, the 
researcher has to be able to decide the best technique 
in accordance to the nature of research. It is also im-
portant to keep in mind that upon saliva collection, 
subsequent centrifugation for removing precipitated 
mucins and cellular contaminants will eliminate some 
proteins of interest. Despite incorporating accurate 
choice of collection system for easy quantification of 
volume with ample sample recovery, other essential 
standardisations of some preanalytical variables 
should always include precise and standardised col-
lection schedules corresponding to individual hydra-
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tion state, body posture, lighting, smoking status, 
circadian and circannual cycles, medications, food 
and visual stimulation, size of salivary glands, body 
weight, salivary flow index, physical exercise, alcohol 
intake, systemic diseases, nutrition, nausea, age, 
gender, and prevention of sample contamination with 
blood from oral mucosa and periodontal lesions [58]. 
Even though potential salivary biomarkers re-
lated to AMI were already discovered, other tests 
should be able to verify the presence of these proteins 
before its further applications. In clinical studies, bi-
omarkers must be robust, distinguishable, and vali-
dated, particularly with regard to which biomarker is 
strongly linked to disease onset and progression. To 
achieve this goal, whole proteome-wide application 
and target biomarker discovery such as MS-based 
proteomics approaches will be able to provide an 
avenue due its higher sensitivity and accuracy in 
identifying and quantifying proteins than immuno-
logical assays [59]. 
Conclusions 
There has been growing interest in diagnosis 
based on analysis of saliva due its simple and 
non-invasive collection procedure. Since saliva collec-
tion is inherently painless, practitioners will be able to 
diagnose and monitor the patients’ wellbeing more 
frequently while approaching the sensitivity and 
specificity of a blood test. Plus, the collection is also 
cheap and safe for both the practitioner and patient. 
With that, patients especially from developing coun-
tries can be diagnosed with minimal costs but great 
precision. 
In summary, human salivary proteomes exhibit 
promising potential as biomarkers to predict the onset 
of AMI particularly among its high-risk group of 
T2DM. Comprehensive analysis of human salivary 
proteome through various methods is indeed neces-
sary in order to find the most reproducible markers 
for later utility in acute cardiac care. It is projected that 
salivary diagnostics will be conclusive such that fewer 
diagnostic biomarkers can be determined with im-
mediate results, thus greatly improving the life qual-
ity of patients. In the long run, more available saliva 
collection kits developed by manufacturing compa-
nies will be able to aid and eventually provide solid 
biomarker findings in future. 
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